Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products
Saved in:
| Published in: | The Oncologist |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products
- Optimal management of venous thromboembolism in adolescent and young adult oncology patients
- Implementing UK Oncology Nursing Society–Informed Digital Symptom Triage With Episode-Based Review in Routine NHS Acute Oncology: Service Evaluation
- Mitotane dosage, plasma levels, and anthropometric measurements in pediatric adrenocortical carcinoma
- Still human: Presence, oncology, and artificial intelligence
- Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts
- Withstanding the test of time for patients in oncology clinical trials